Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

546 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group.
Mosele MF, Westphalen CB, Stenzinger A, Barlesi F, Bayle A, Bièche I, Bonastre J, Castro E, Dienstmann R, Krämer A, Czarnecka AM, Meric-Bernstam F, Michiels S, Miller R, Normanno N, Reis-Filho J, Remon J, Robson M, Rouleau E, Scarpa A, Serrano C, Mateo J, André F. Mosele MF, et al. Among authors: bieche i. Ann Oncol. 2024 Jul;35(7):588-606. doi: 10.1016/j.annonc.2024.04.005. Epub 2024 May 27. Ann Oncol. 2024. PMID: 38834388 Free article.
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane.
Vanacker H, Treilleux I, Schiffler C, Bieche I, Campone M, Patsouris A, Arnedos M, Cottu PH, Jacquin JP, Dalenc F, Pinton A, Servant N, Attignon V, Rouleau E, Morel A, Legrand F, Jimenez M, Andre F, Bachelot T. Vanacker H, et al. Among authors: bieche i. Br J Cancer. 2024 Mar;130(4):613-619. doi: 10.1038/s41416-023-02549-8. Epub 2024 Jan 5. Br J Cancer. 2024. PMID: 38182687
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors.
Sablin MP, Gestraud P, Jonas SF, Lamy C, Lacroix-Triki M, Bachelot T, Filleron T, Lacroix L, Tran-Dien A, Jézéquel P, Mauduit M, Barros Monteiro J, Jimenez M, Michiels S, Attignon V, Soubeyran I, Driouch K, Servant N, Le Tourneau C, Kamal M, André F, Bièche I. Sablin MP, et al. Among authors: bieche i. Br J Cancer. 2024 Oct;131(6):1060-1067. doi: 10.1038/s41416-024-02804-6. Epub 2024 Aug 2. Br J Cancer. 2024. PMID: 39090361 Free PMC article.
Metastatic renal cell carcinoma with occult primary: a multicenter prospective cohort.
Jacquin N, Flippot R, Masliah-Planchon J, Grisay G, Brillet R, Dupain C, Kamal M, Guillou I, Gruel N, Servant N, Gestraud P, Wong J, Cockenpot V, Goncalves A, Selves J, Blons H, Rouleau E, Delattre O, Gervais C, Le Tourneau C, Bièche I, Allory Y, Albigès L, Watson S. Jacquin N, et al. Among authors: bieche i. NPJ Precis Oncol. 2024 Jul 18;8(1):147. doi: 10.1038/s41698-024-00648-0. NPJ Precis Oncol. 2024. PMID: 39025947 Free PMC article.
The genomic and transcriptomic landscape of metastastic urothelial cancer.
Loriot Y, Kamal M, Syx L, Nicolle R, Dupain C, Menssouri N, Duquesne I, Lavaud P, Nicotra C, Ngocamus M, Lacroix L, Tselikas L, Crehange G, Friboulet L, Castel-Ajgal Z, Neuzillet Y, Borcoman E, Beuzeboc P, Marret G, Gutman T, Wong J, Radvanyi F, Dureau S, Scoazec JY, Servant N, Allory Y, Besse B, Andre F, Le Tourneau C, Massard C, Bieche I. Loriot Y, et al. Among authors: bieche i. Nat Commun. 2024 Oct 4;15(1):8603. doi: 10.1038/s41467-024-52915-0. Nat Commun. 2024. PMID: 39366934 Free PMC article.
Multi-Institutional Evaluation of Interrater Agreement of Biomarker-Drug Pair Rankings Based on the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) and Sources of Discordance.
Lebedeva A, Belova E, Kavun A, Taraskina A, Bartoletti M, Bièche I, Curigliano G, Dupain C, Rios-Hoyo A, Kamal M, Luchini C, Poyarkov S, Le Tourneau C, Veselovsky E, Mileyko V, Ivanov M. Lebedeva A, et al. Among authors: bieche i. Mol Diagn Ther. 2024 Oct 5. doi: 10.1007/s40291-024-00748-4. Online ahead of print. Mol Diagn Ther. 2024. PMID: 39368036
Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine.
Dupain C, Gutman T, Girard E, Kamoun C, Marret G, Castel-Ajgal Z, Sablin MP, Neuzillet C, Borcoman E, Hescot S, Callens C, Trabelsi-Grati O, Melaabi S, Vibert R, Antonio S, Franck C, Galut M, Guillou I, Halladjian M, Allory Y, Cyrta J, Romejon J, Frouin E, Stoppa-Lyonnet D, Wong J, Le Tourneau C, Bièche I, Servant N, Kamal M, Masliah-Planchon J. Dupain C, et al. Among authors: bieche i. BMC Biol. 2024 Feb 20;22(1):43. doi: 10.1186/s12915-024-01839-8. BMC Biol. 2024. PMID: 38378561 Free PMC article.
546 results